EU Approves Alexion’s Koselugo for Adults with Neurofibromatosis Type 1
Alexion, AstraZeneca Rare Disease, announced that the European Commission has approved Koselugo (selumetinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN)…
Read More...
Read More...
